Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monalizumab in resectable oral cavity squamous cell carcinoma
NCT02331875Phase 2
Key facts
- Status
- Terminated
- Start
- Dec 2014
- Primary completion
- Dec 2016
- Countries
- 2
- Sponsor
- Innate Pharma
- Modality
- Monoclonal Antibodies
- Drugs
- monalizumab
- Conditions
- squamous cell carcinoma of the oral cavity (OSCC)
01
Overview
Phase 2, open-label, single-arm trial of monalizumab in squamous cell carcinoma of the oral cavity (OSCC), sponsored by Innate Pharma. Primary endpoint: Best Objective Response Rate at 8 weeks. Started Dec 2014; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Monalizumab Arm
Patients receive neoadjuvant monalizumab followed by surgery and adjuvant therapy.
03
Who it enrols
Patients with histologically confirmed, primary, previously untreated, resectable squamous cell carcinoma of the oral cavity (Stage II-IVa).
04
Endpoints
Primary
Best Objective Response Rate
Beyond the preview
Go deeper on NCT02331875.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02331875.